Bevacizumab biosimilar (mAbixience)

贝伐珠单抗生物类似药 (mAbixience)

Report date: 2026/05/26 20:00:28

Base Information

Drug NameBevacizumab biosimilar (mAbixience)

Drug Alias Name贝伐赛珠单抗生物仿制药 (mAbixience)贝伐单抗生物仿制药 (mAbixience)贝伐珠单抗生物仿制药 (mAbixience)贝伐人源化单抗生物仿制药 (mAbixience)Alymsys +[9]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9]

Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9]

Approved Indications in ChinaN/A

Original Approved Country/TerritoryArgentina

Original Approved Date2013/10/25

Country/TerritoryUnited StatesNew ZealandGermany +[6]

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesMabxience Sa

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9]

Inactive IndicationsN/A

ATC CodeL01XC07